Recent Quotes (30 days)

You have no recent quotes
chg | %

Sophiris Bio Inc  

(Public, TSE:SHS)   Watch this stock  
Find more results for TSE:PRX
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 4.25 - 18.20
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -4.35
Shares     -
Beta     -
Inst. own     -
Dec 2, 2014
Sophiris Bio Inc at Piper Jaffray Healthcare Conference
Nov 18, 2014
Sophiris Bio Inc at Stifel Healthcare Conference
Nov 12, 2014
Q3 2014 Sophiris Bio Inc Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -222.98%
Operating margin - -195.80%
EBITD margin - -194.12%
Return on average assets -92.87% -35.16%
Return on average equity -141.30% -63.39%
Employees 8 -
CDP Score - -


1258 Prospect Street
LA JOLLA, CA 92037
United States - Map
+1-858-7771760 (Phone)
+1-858-4125693 (Fax)

Website links


Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Officers and directors

Lars G. Ekman M.D., Ph.D. Executive Chairman of the Board
Randall E. Woods President, Chief Executive Officer, Director
Age: 62
Peter T. Slover CPA Chief Financial Officer
Age: 39
Allison J. Hulme Ph.D. Chief Operating Officer, Head - Research & Development
Age: 51
John Geltosky Ph.D. Independent Director
Age: 68
James L. Heppell Independent Director
Age: 58
Gerald T. Proehl Independent Director
Age: 55
Joseph L. Turner Jr. Independent Director
Age: 62